693 related articles for article (PubMed ID: 33685998)
1. SARS-CoV-2 vaccines in patients with SLE.
Tang W; Askanase AD; Khalili L; Merrill JT
Lupus Sci Med; 2021 Mar; 8(1):. PubMed ID: 33685998
[TBL] [Abstract][Full Text] [Related]
2. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis.
Bartels LE; Ammitzbøll C; Andersen JB; Vils SR; Mistegaard CE; Johannsen AD; Hermansen MF; Thomsen MK; Erikstrup C; Hauge EM; Troldborg A
Rheumatol Int; 2021 Nov; 41(11):1925-1931. PubMed ID: 34476603
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
4. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
5. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
Gargano JW; Wallace M; Hadler SC; Langley G; Su JR; Oster ME; Broder KR; Gee J; Weintraub E; Shimabukuro T; Scobie HM; Moulia D; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(27):977-982. PubMed ID: 34237049
[TBL] [Abstract][Full Text] [Related]
6. Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.
Zavala-Flores E; Salcedo-Matienzo J; Quiroz-Alva A; Berrocal-Kasay A
Clin Rheumatol; 2022 May; 41(5):1349-1357. PubMed ID: 34782941
[TBL] [Abstract][Full Text] [Related]
7. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.
Oliver SE; Gargano JW; Marin M; Wallace M; Curran KG; Chamberland M; McClung N; Campos-Outcalt D; Morgan RL; Mbaeyi S; Romero JR; Talbot HK; Lee GM; Bell BP; Dooling K
MMWR Morb Mortal Wkly Rep; 2020 Dec; 69(50):1922-1924. PubMed ID: 33332292
[TBL] [Abstract][Full Text] [Related]
8. Lupus, vaccinations and COVID-19: What we know now.
Mason A; Anver H; Lwin M; Holroyd C; Faust SN; Edwards CJ
Lupus; 2021 Sep; 30(10):1541-1552. PubMed ID: 34134555
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study.
Naveen R; Nikiphorou E; Joshi M; Sen P; Lindblom J; Agarwal V; Lilleker JB; Tan AL; Salim B; Ziade N; Velikova T; Gracia-Ramos AE; Kuwana M; Day J; Makol A; Distler O; Chinoy H; Traboco LS; Wibowo SAK; Tehozol EAZ; Serrano JR; García-De La Torre I; ; Aggarwal R; Gupta L; Agarwal V; Parodis I
Rheumatology (Oxford); 2023 Jul; 62(7):2453-2463. PubMed ID: 36413073
[TBL] [Abstract][Full Text] [Related]
10. Immune Thrombocytopenia Following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine.
Ganzel C; Ben-Chetrit E
Isr Med Assoc J; 2021 Jun; 23(6):341. PubMed ID: 34155844
[No Abstract] [Full Text] [Related]
11. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021.
Wallace M; Woodworth KR; Gargano JW; Scobie HM; Blain AE; Moulia D; Chamberland M; Reisman N; Hadler SC; MacNeil JR; Campos-Outcalt D; Morgan RL; Daley MF; Romero JR; Talbot HK; Lee GM; Bell BP; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 May; 70(20):749-752. PubMed ID: 34014913
[TBL] [Abstract][Full Text] [Related]
12. New-onset systemic lupus erythematosus following BNT162b2 mRNA COVID-19 vaccine: a case series and literature review.
Sagy I; Zeller L; Raviv Y; Porges T; Bieber A; Abu-Shakra M
Rheumatol Int; 2022 Dec; 42(12):2261-2266. PubMed ID: 36098769
[TBL] [Abstract][Full Text] [Related]
13. FDA authorizes Pfizer-BioNTech COVID-19 vaccine.
Med Lett Drugs Ther; 2021 Jan; 63(1615):1-2. PubMed ID: 33646996
[No Abstract] [Full Text] [Related]
14. A 12-month follow-up study of patients with systemic lupus erythematosus after immunization against SARS-CoV-2.
Zavala-Flores E; Salcedo-Matienzo J; Huamanchumo-Guzman R; Berrocal-Kasay A; Alarcón GS
Lupus; 2024 Mar; 33(3):282-288. PubMed ID: 38237938
[TBL] [Abstract][Full Text] [Related]
15. Systemic lupus erythematosus with acute pancreatitis and vasculitic rash following COVID-19 vaccine: a case report and literature review.
N AM; Saleh AM; Khalid A; Alshaya AK; Alanazi SMM
Clin Rheumatol; 2022 May; 41(5):1577-1582. PubMed ID: 35175446
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of newly diagnosed systemic lupus erythematosus after SARS-CoV-2 vaccination.
Moriyama M; Noda K; Ito H; Matsushita T; Kurosaka D
Mod Rheumatol Case Rep; 2023 Dec; 8(1):63-68. PubMed ID: 37348045
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.
Schulze-Koops H; Specker C; Skapenko A
RMD Open; 2021 Feb; 7(1):. PubMed ID: 33627439
[TBL] [Abstract][Full Text] [Related]
18. Systemic lupus erythematosus following COVID-19 vaccination. A systematic review of case reports and case series.
Cahuapaza-Gutierrez NL
Lupus; 2024 Apr; 33(4):375-386. PubMed ID: 38315894
[TBL] [Abstract][Full Text] [Related]
19. Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus.
Mok CC; Chan KL; Tse SM
Vaccine; 2022 Sep; 40(41):5959-5964. PubMed ID: 36085256
[TBL] [Abstract][Full Text] [Related]
20. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus.
Yoshida T; Tsuji H; Onishi A; Takase Y; Shirakashi M; Onizawa H; Hiwa R; Kitagori K; Akizuki S; Nakashima R; Tanaka M; Yoshifuji H; Morinobu A
Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 35961691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
